Media headlines about MEI Pharma (NASDAQ:MEIP) have trended somewhat positive on Sunday, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MEI Pharma earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.0578517893154 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- NEA Management Company, LLC Buys Surface Oncology Inc, MEI Pharma Inc, Tintri Inc, Sells CRISPR Therapeutics … (gurufocus.com)
- Analysts Expect MEI Pharma Inc (MEIP) to Post -$0.22 Earnings Per Share (americanbankingnews.com)
- MEI Pharma Inc (MEIP) COO David M. Urso Sells 9,500 Shares (americanbankingnews.com)
- Active Daily Watch List: PEDEVCO Corp. (PED), MEI Pharma, Inc. (MEIP) (newsregistrar.com)
MEI Pharma stock remained flat at $$3.64 during trading on Friday. 148,389 shares of the company were exchanged, compared to its average volume of 359,640. MEI Pharma has a one year low of $1.79 and a one year high of $5.14. The stock has a market capitalization of $135.86 million, a P/E ratio of 52.00 and a beta of 1.93.
MEI Pharma (NASDAQ:MEIP) last issued its quarterly earnings results on Wednesday, May 9th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.08. The company had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.40 million. MEI Pharma had a negative net margin of 1,651.87% and a negative return on equity of 60.75%. sell-side analysts predict that MEI Pharma will post -0.81 EPS for the current fiscal year.
A number of brokerages recently weighed in on MEIP. Stifel Nicolaus upgraded shares of MEI Pharma from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Thursday, July 26th. Zacks Investment Research cut shares of MEI Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, July 18th. ValuEngine upgraded shares of MEI Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Cann reiterated a “buy” rating on shares of MEI Pharma in a research note on Monday, July 9th. Finally, SunTrust Banks started coverage on shares of MEI Pharma in a research note on Friday, July 13th. They issued a “buy” rating and a $12.00 price target for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. MEI Pharma has a consensus rating of “Buy” and a consensus price target of $7.42.
In other news, COO David M. Urso sold 9,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $3.58, for a total transaction of $34,010.00. Following the completion of the sale, the chief operating officer now owns 33,606 shares in the company, valued at approximately $120,309.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.25% of the stock is currently owned by insiders.
MEI Pharma Company Profile
MEI Pharma, Inc, an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Featured Story: Dividend
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.